Ankylosing spondylitis in sub-Saharan Africa

被引:25
作者
Belachew, D. A. [1 ]
Sandu, N. [1 ]
Schaller, B. [1 ]
Guta, Z. [1 ]
机构
[1] Univ Addis Ababa, Fac Med, Dept Neurol, Addis Ababa, Ethiopia
关键词
DOUBLE-BLIND; SULFASALAZINE; PLACEBO; SPONDYLARTHROPATHIES; SPONDYLOARTHRITIS; METHOTREXATE; THERAPY; RISK;
D O I
10.1136/pgmj.2007.064717
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ankylosing spondylitis (AS) represents a chronic inflammatory bone disease of the axial skeleton that manifests as chronic back pain and progressive stiffness of the spine. It characteristically affects young adults with a peak age of onset between 20-30 years. In contrast to Western Europe and North America, the disease is rare in Sub-Saharan Africa where the majority of the population is HLA-B27 negative. Even in some African populations where HLA-B27 is prevalent (for example, in Gambia and Senegal, where 3-6% of the general population has HLA-B27), the disease is also said to be rare. However, some other genetic markers may be involved in the causation of AS in the HLA-B27 negative population, and when it occurs in this subgroup of patients it has a similar manifestation with HLA-B27 negative white patients and these patients rarely develop anterior uveitis. The clinical presentation of the disease in Africa is generally milder; most affected individuals do not have a family history of AS, the patients are older at onset of the disease, and the majority of them lack extra-articular manifestations such as anterior uveitis compared with the situation in Western Europe and North America. In conclusion, AS in sub-Saharan Africa seems to represent a subgroup of the disease, which may open the window to a greater understanding of the pathophysiology of the condition.
引用
收藏
页码:353 / 357
页数:5
相关论文
共 42 条
[1]   Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept:: Clinical and magnetic resonance imaging data [J].
Baraliakos, X ;
Brandt, J ;
Listing, J ;
Haibel, H ;
Sörensen, H ;
Rudwaleit, M ;
Sieper, J ;
Braun, J .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2005, 53 (06) :856-863
[2]   CAUDA-EQUINA SYNDROME SECONDARY TO LONG-STANDING ANKYLOSING-SPONDYLITIS [J].
BARTLESON, JD ;
COHEN, MD ;
HARRINGTON, TM ;
GOLDSTEIN, NP ;
GINSBURG, WW .
ANNALS OF NEUROLOGY, 1983, 14 (06) :662-669
[3]  
Belachew DA, 2007, ARCH MED SCI, V3, P315
[4]   EARLY SACROILIITIS IN PATIENTS WITH SPONDYLOARTHROPATHY - EVALUATION WITH DYNAMIC GADOLINIUM-ENHANCED MR-IMAGING [J].
BOLLOW, M ;
BRAUN, J ;
HAMM, B ;
EGGENS, U ;
SCHILLING, A ;
KONIG, H ;
WOLF, KJ .
RADIOLOGY, 1995, 194 (02) :529-536
[5]  
Braun J, 1998, ARTHRITIS RHEUM-US, V41, P58, DOI 10.1002/1529-0131(199801)41:1<58::AID-ART8>3.3.CO
[6]  
2-7
[7]   Ankylosing spondylitis [J].
Braun, Juergen ;
Sieper, Joachim .
LANCET, 2007, 369 (9570) :1379-1390
[8]  
Brophy S, 2002, J RHEUMATOL, V29, P1236
[9]   Ankylosing spondylitis in west Africans - Evidence for a non-HLA-B27 protective effect [J].
Brown, MA ;
Jepson, A ;
Young, A ;
Whittle, HC ;
Greenwood, BM ;
Wordsworth, BP .
ANNALS OF THE RHEUMATIC DISEASES, 1997, 56 (01) :68-70
[10]   Non-major-histocompatibility-complex genetics of ankylosing spondylitis [J].
Brown, Matthew A. .
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2006, 20 (03) :611-621